Core Viewpoint - Netflix has announced a 10-for-1 stock split, reflecting its significant growth and investor confidence since its last split in 2015, with shares now trading well above $1,000 [1][2] Financial Performance - Netflix's third-quarter revenue increased by 17.2% year over year, up from 15.9% in the second quarter, with management guiding for another 17% increase in the fourth quarter [3] - The company's operating margin is projected to expand from 27% in 2024 to 29% in 2025, indicating strong core business performance [5] Advertising Business - The advertising segment, although still small, is growing rapidly and is expected to more than double its revenue by 2025, providing an additional growth avenue beyond subscriber increases and price hikes [4] - The fast-growing advertising business is anticipated to significantly bolster profits over time [4][8] Stock Valuation - Netflix's current price-to-earnings (P/E) ratio exceeds 47, but its forward P/E ratio is more reasonable at 35, reflecting the company's growth potential and market leadership [7][8] - The stock split does not alter the company's intrinsic value; it merely changes the number of shares held by investors [6] Market Context - The competitive landscape remains intense, with significant competition from well-funded tech companies, necessitating cautious investment strategies [9]

Retirees can expect big changes next year -- both good and not-so-good.Next year will bring a slew of changes to the Social Security program, from a new cost-of-living adjustment (COLA) to a higher maximum benefit to raised earnings test limits.But not all of the changes are positive, and there's some not-so-good news awaiting retirees in 2026, too. Here's everything retirees need to know about what's ahead with Social Security. Big changes are coming in 2026Let's start with the good news: Your benefit will ...

Core Insights - Coca-Cola Consolidated's stock surged 15.8% following a $2.4 billion stock buyback from The Coca-Cola Company, reflecting strong investor sentiment [1][2][3] - The stock is up approximately 26% year to date, indicating positive market performance [2] - The buyback enhances Coca-Cola Consolidated's autonomy and may lead to increased pricing flexibility, as The Coca-Cola Company also relinquished its board seat [3] Financial Data - Market capitalization stands at $14 billion [5] - Current stock price is $159.54, with a day's range of $158.01 to $161.93 [4][5] - The stock has a gross margin of 38.60% and a dividend yield of 0.01% [5] Market Context - The stock benefited from a sector rotation as investors shifted from speculative stocks to safer investments, contributing to its valuation boost [5]

Core Viewpoint - Arqit Quantum's stock experienced a significant decline despite the launch of a new software platform, primarily due to macroeconomic and geopolitical concerns affecting speculative growth stocks [1][2][3] Company Developments - Arqit launched the SKA Central Controller, a network security platform aimed at providing encryption against quantum-based attacks, which could be pivotal for the company's growth [5] - For the current fiscal year, Arqit is projecting sales of approximately $1.2 million, a substantial increase from the previous year's guidance of around $530,000 [6] Market Performance - The stock price of Arqit Quantum fell by 18.9% over the last week of trading, reflecting a broader trend of investors moving away from speculative growth stocks [1][2] - The company's market capitalization stands at $394.5 million, indicating that strong growth expectations are already factored into the stock price [6] - The stock has seen a year-to-date decline of 29% as of the latest trading period [3]

Core Insights - The iShares Core High Dividend ETF (HDV) and the Schwab U.S. Dividend Equity ETF (SCHD) both focus on U.S. dividend stocks, with SCHD noted for its lower cost, higher yield, and larger assets under management, while HDV has shown stronger recent returns [1][2] Cost & Size Comparison - HDV has an expense ratio of 0.08% and assets under management (AUM) of $11.6 billion, while SCHD has a lower expense ratio of 0.06% and significantly larger AUM of $70.1 billion [3][4] - The 1-year return for HDV is 3.6%, whereas SCHD has a negative return of (5.7%), and the dividend yield for HDV is 3.1% compared to SCHD's 3.8% [3][4] Performance & Risk Analysis - Over a 5-year period, $1,000 invested in SCHD would grow to approximately $1,400, while the same investment in HDV would grow to about $1,300 [5] - SCHD tracks a portfolio of 103 U.S. dividend payers with significant sector exposure to energy (20%), consumer defensive (18%), and healthcare (16%) [5][6] - HDV selects 75 stocks with a heavier tilt towards consumer defensive (25%), energy (22%), and healthcare (20%) [6] Historical Returns - Over the past 10 years, SCHD delivered a total return of 199.5%, while HDV underperformed with a total return of 143.1% [7] - The latest quarterly payment for HDV was only 2.85% higher than five years ago, indicating disappointing growth in payouts for income-seeking investors [8] - In contrast, SCHD's focus on dividend growth led to a 29.9% increase in its dividend payout over the past five years [9]

Core Insights - Tower Semiconductor's Q3 report exceeded Wall Street expectations, leading to an 18.1% increase in stock price despite a general decline in chip stocks [1][2] - The company's earnings per share were $0.47, surpassing analyst estimates by $0.02, while sales reached $396 million, exceeding forecasts by $1 million [2] - Year-over-year revenue growth was 7%, with gross profit rising to $93 million from $80 million in the previous year [4] Financial Performance - The current market capitalization of Tower Semiconductor is $11 billion [3] - The gross margin for the quarter was 22.01%, and operating cash flow was $139 million, representing a margin of 31.6% [4] - For Q4, the company projects sales of $440 million, indicating a potential annual growth of 14% and sequential growth of 11% [5] Growth Drivers - Tower Semiconductor is experiencing growth across all core product segments, including power management, image sensors, and 65nm RF mobile [6] - There is increasing demand from artificial intelligence (AI) data centers, which is positively impacting the company's growth outlook [6]

Company Overview - ACM Research is a leading provider of advanced wafer processing equipment for the semiconductor industry, specializing in single-wafer cleaning and plating technologies [4][8] - The company leverages proprietary innovations such as space alternated phase shift and timely energized bubble oscillation to meet the needs of cutting-edge chip fabrication [4][8] - As of November 14, 2025, ACM Research's market capitalization was $2.12 billion, with a revenue of $880.35 million and a net income of $117.11 million for the trailing twelve months (TTM) [3] Recent Developments - Seldon Capital LP disclosed a new position in ACM Research, adding 193,242 shares valued at approximately $7.56 million as of September 30, 2025 [1] - This new position represents 2.66% of Seldon Capital's total assets under management (AUM) [2] - ACM Research shares were priced at $31.51 on November 14, 2025, with a one-year total return of 68.2%, outperforming the S&P 500 by 57 percentage points [2] Financial Performance - In Q3 2025, ACM Research reported a 32% year-over-year increase in sales, reaching $269.2 million [9] - The company expects full-year revenue to be between $875 million and $925 million, indicating significant growth compared to 2024's revenue of $782.1 million [9] - ACM Research's diluted earnings per share (EPS) increased to $1.26 in the first three quarters of 2025, up from $1.07 in 2024 [10] Market Position - ACM Research positions itself as a key enabler of next-generation semiconductor production, focusing on enhancing manufacturing yields [5] - The company sells proprietary equipment and technology solutions to integrated circuit manufacturers through a direct sales force and third-party representatives [8]

Core Viewpoint - Nvidia is poised to achieve record data center revenue, driven by high demand for its GPUs and a significant order backlog of $500 billion for new chips over the next five quarters [1][6][12] Group 1: Financial Outlook - Nvidia's CEO Jensen Huang announced a $500 billion order book for the new Blackwell and Rubin GPUs, indicating strong future revenue potential [5][6] - The actual backlog figure is estimated to be closer to $307 billion, which is expected to be recognized over the next year [11] - Nvidia's data center division is now generating more than $30 billion in revenue quarterly, showcasing substantial growth compared to previous years [12][13] Group 2: Market Reaction - Following the announcement of the order backlog, Nvidia's market capitalization surged to over $5 trillion [6] - Investors are optimistic about Nvidia's growth trajectory, which is expected to exceed Wall Street's current expectations [14][16] Group 3: Product Demand and Development - The demand for Nvidia's GPUs has created a virtuous cycle of sales and reinvestment into developing more powerful architectures [3][10] - Approximately 30% of the demand for Blackwell chips relates to units already shipped, meaning some revenue has already been recognized [10] Group 4: Investment Perspective - Nvidia's forward price-to-earnings (P/E) ratio of 30 is considered reasonable given its robust sales pipeline and expanding profitability [16] - Nvidia is viewed as a compelling buy-and-hold opportunity for technology investors, suitable for long-term portfolios [17]

Core Viewpoint - The Trump administration has reached a deal with pharmaceutical companies Novo Nordisk and Eli Lilly to significantly reduce the prices of weight loss drugs through a national online platform called TrumpRx, which may benefit consumers but could impact the drugmakers' profitability [1][2][12]. Group 1: Drug Pricing and Market Impact - The agreement allows Novo Nordisk's Wegovy and Eli Lilly's Zepbound to be sold at steep discounts, with Wegovy priced at $350 for a one-month supply and Zepbound at an average of $346 through TrumpRx [10]. - Wegovy's list price is over $1,349 for a 28-day supply, while Zepbound costs more than $1,250, making them potentially unaffordable for lower-income households without assistance [8][7]. - The Medicare prices for these drugs will be set at $245, with eligible patients paying a copay of $50 [11]. Group 2: Sales Growth and Market Demand - Wegovy's popularity has surged, contributing to Novo Nordisk's recognition, while Zepbound's sales increased from approximately $517 million in Q1 2024 to nearly $3.6 billion in Q3 2024 [4]. - A Gallup survey indicated that the percentage of respondents who have taken weight loss injections more than doubled from Q1 2024 to Q3 2025, suggesting growing demand for these treatments [6]. - The potential for increased demand from a budget-constrained population raises questions about the impact on sales volume and profit margins for both companies [15][16]. Group 3: Future Considerations and Investor Insights - The success of TrumpRx is uncertain, and its implementation may face challenges similar to previous policy efforts by the Trump administration [14]. - Investors should monitor adjustments in quarterly earnings guidance from Novo Nordisk and Eli Lilly, as well as potential analyst revisions related to the TrumpRx rollout [17]. - Given the current uncertainties surrounding TrumpRx, investment decisions regarding Novo Nordisk and Eli Lilly should not be solely based on this initiative [18].

On Nov. 14, 2025, 4D Advisors, LLC disclosed in a regulatory filing that it sold out its entire position in Masimo (MASI 0.92%). The sale was valued at $7.57 million.What happenedAccording to a filing with the Securities and Exchange Commission dated November 14, 2025, 4D Advisors, LLC reported selling its entire stake in Masimo. The fund exited by selling 45,000 shares, with the transaction value being approximately $7,569,900, based on average pricing during the quarter. The firm held 0 shares of Masimo a ...